January 31, 2011
Rituxan gains indication for first-line maintenance use in follicular lymphoma
Rituxan is already indicated for relapsed or refractory, low-grade or follicular, CD20(+), B-cell non-Hodgkin's lymphoma (NHL); first-line treatment of follicular, CD20(+), B-cell NHL in combination with CVP chemotherapy; non-progressing (including stable disease), low-grade, CD20(+), B-cell NHL following 1st line CVP chemotherapy; first-line treatment of diffuse large B-cell, CD20(+) NHL in combination with CHOP or other anthracycline-based chemotherapy regimens; and in combination with fludarabine and cyclophosphamide for previously untreated and previously treated CD-20 positive chronic lymphocytic leukemia. Rituxan is also indicated in combination with methotrexate to reduce signs/symptoms and inhibit progression of structural damage in moderately-to-severely active rheumatoid arthritis patients who have had an inadequate response to one or more TNF antagonist therapies.
For more information call (800) 821-8590 or visit www.rituxan.com.